Bolivia Medical Device Price Compliance: Circular 1/2021 and Ley N° 1737

1. Key takeaways

On 6 January 2021, AGEMED issued Circular MSyD/AGEMED/CR/1/2021 publishing a price list, accompanied by Resolución Administrativa N° 001 of 6 January 2021, which approved the price list for medicines and consumables in the context of the COVID-19 pandemic. The legal basis cited by the circular is Article 1(e) of Ley N° 1737 of 17 December 1996, under which the national medicines policy must establish decentralized mechanisms for procurement, supply, distribution, and the control of prices at the origin of imports, and Article 59 of the same law, which classifies violations of the law and its implementing regulations as punishable conduct, including speculation and hoarding. The GRZAN conclusion is direct: price compliance in Bolivia is an obligation written into the law itself, and a medical device company cannot avoid it on the argument that it deals only in devices.

The COVID-19 origin of the 2021 list does not weaken the point. A measure adopted in a public health emergency, resting on standing provisions of the medicines law, demonstrates how quickly price controls can be activated and how broad the addressee group is. For device companies the lesson is one of preparedness: the pricing file for each product should already contain the cost build-up, the import value at origin, and the commercial justification, so that if a device category is added to a future list, the company can respond with documentation rather than improvisation. GRZAN treats the price file as part of the post-market dossier for Bolivia precisely because the legal basis for such lists already exists and has been exercised within living memory of current projects.

2. Legal basis

3. Expert insights

Insight one: the legal source of price control is the national medicines policy, and devices fall within that policy. The mechanism established by Article 1(e) covers procurement, supply, distribution, and the control of prices at the origin of imports. Because Article 2 of the same law brings medical devices within its scope, the mechanism has a legal foundation that reaches devices. The addressees of Circular 1/2021 include departmental and municipal health services, private pharmacies and clinics, and importers and distributors, so the coverage is broad. A device importer or distributor in Bolivia is inside the population the circular addresses, whether or not the company thinks of itself as a pharmaceutical actor.

Insight two: speculation and hoarding are punishable conduct, which creates a supply-side compliance risk. Article 59 lists speculation and hoarding among punishable violations of the law. For a device company, this means that pricing and supply strategies during periods of shortage may touch this provision, not only the price figures themselves. Withholding stock to push prices upward, or channeling supply in ways that a regulator could characterize as hoarding, converts a commercial decision into an enforcement exposure under a statute that also anchors the company sanitary registration. Supply commitments made to distributors should therefore include a compliance reservation, so that commercial pressure during a shortage cannot push the local partner into conduct the manufacturer would never accept in its own name.

Insight three: the price list is dynamic, not static. Circular 1/2021 uses the wording of an updated list, which shows that price lists in Bolivia are adjusted over time rather than issued once. Companies should treat the list as an object of continuous compliance tracking rather than as a one-time action at launch. A price list reviewed only at market entry will silently drift out of date, and the drift becomes visible precisely when a contract tender or an inspection calls for current documentation. A quarterly review of the price tracking file, with the responsible person named in the SOP, is enough to keep the exposure bounded.

4. Practical recommendations

1. Bring price compliance into launch planning, evaluating the impact of public procurement and the price list at the pricing strategy stage, before commercial commitments are made to distributors or institutions.
2. Include supply and pricing compliance clauses in the distribution agreement, expressly prohibiting speculative or hoarding conduct by the importer and defining how price list updates are communicated and implemented.
3. Place AGEMED price-related circulars on the quarterly tracking list, watching for list updates and for any extension of price controls to additional categories of health products.

The public procurement channel deserves separate attention. Hospitals and public institutions purchase a large share of health products in Bolivia, and tenders typically reference published price documentation. A company whose internal price file disagrees with what it charges in a tender invites exactly the comparison the Article 1(e) mechanism is designed to perform. Aligning the tender price, the distributor price, and the documented import value is therefore not only good governance but the practical defense if the pricing of a product is ever questioned. GRZAN reviews this alignment as part of post-market compliance work, because a price question rarely arrives as a price question; it arrives as a document request during an unrelated inspection. Keeping the alignment file current costs a few hours per quarter and removes one of the few compliance exposures that arises from ordinary commercial behavior rather than from regulatory paperwork.

5. Verification checklist

• □ Has the current validity of Circular 1/2021 and its accompanying administrative resolution been confirmed?
• □ Do the target products fall within the scope of the price list?
• □ Has the applicability of the Article 59 provisions on speculation and hoarding been assessed for this business model?
• □ Does the distribution agreement contain pricing and supply compliance clauses?
• □ Have price-related circulars been added to the quarterly tracking list?

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers, importers, and authorized representatives with sanitary registration, pricing compliance, and post-market obligations in Bolivia. For assistance with this topic, contact info@grzanglobal.com.